All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Multiple Myeloma Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View multiple myeloma content recommended for you

ASH 21

Share:

Mar 4, 2022

X post image

9 Jul 2022

71% of pts reached an MRD-free, treatment-free state, with a low risk of MRD reappearance after 12 months in selected subgroups.
#ASH21 #mmsm #myeloma

X post image

5 May 2022

📹 Catch up on this video from #ASH21
The Multiple Myeloma Hub was pleased to speak to @mvmateos, University Hospital of Salamanca. We asked, What can we achieve with novel mass spectrometry techniques ❓
#mmsm #myeloma

https://t.co/89tDPXDt7X

X post image

3 May 2022

🎧 Re-listen to this #ASH21 podcast 👇

The MM Hub spoke to Jacob Laubach, @DanaFarber & Peter Voorhees, @LevineCancer. We asked, Daratumumab as maintenance therapy for transplant-eligible NDMM: What have we learnt from GRIFFIN & CASSIOPEIA trials❓
https://t.co/EOuwMqIXzD

X post image

30 Apr 2022

Did you miss this❓👀

After 2 years of maintenance therapy with daratumumab + lenalidomide, what results have been seen in the Griffin trial for patients with NDMM? Find a summary of the data reported at #ASH21 here 👇

👉 https://t.co/cro1SoItWa 👈
#myeloma #mmsm

X post image

27 Apr 2022

Did you miss this? 👇

🔎 Updated results of the phase I MagnetisMM-1 trial of elranatamab in patients with relapsed/refractory multiple #myeloma were presented at #ASH21. To find out the new ORR and safety data, check out our summary here
👉 https://t.co/GDICAhfi1i 👈
#mmsm

X post image

16 Apr 2022

71% of pts reached an MRD-free, treatment-free state, with a low risk of MRD reappearance after 12 months in selected subgroups.
#ASH21 #mmsm #myeloma

X post image

15 Apr 2022

Catch up on this, presented at #ASH21 👀

What were the key findings of the @iStopMM trial? 📚 Read our article for a summary 👇

👉 https://t.co/0u7iUPrpFc 👈
#mmsm #myeloma @SigrunThorstei1 @sykristinsson

X post image

14 Apr 2022

👀 Modakafusp alfa (TAK-573) is a first-in-class immunocytokine designed to deliver IFNα2b to CD38+ cells. Read the initial results presented at #ASH21 by Dan Vogl @PennCancer from the ongoing phase I trial here 👇
👉 https://t.co/6C2uSA1miQ 👈

#mmsm #myeloma

X post image

9 Apr 2022

Catch up on this from ASH21 👀👇

🔎 Results of the GMMG-HD7 trial from #ASH21. How did the CD38 monoclonal antibody impact MRD when added to RVd❓

👉 https://t.co/VMf4QKWz9C 👈
#mmsm #myeloma

X post image

2 Apr 2022

Did you miss this?👇
Is dara-(C)VRd pre- & post-ASCT the way forward for treatment of high-risk MM & PCL❓ Are digital comparators the future of trial design? 📚 Check out our summary of @MyMKaiser presenting data from OPTIMUM/MUKnine at #ASH21
👉 https://t.co/l91Ih0ClYT 👈

X post image

24 Mar 2022

📚The updated results from REGN5458 phase I study were presented by @Amyloid_Planet, @karmanoscancer at #ASH21. Read the latest on this novel BCMAxCD3 #bispecific antibody for R/R #myeloma, now recruiting for its phase II trial.

👉 https://t.co/s9aM0TO44z 👈

#mmsm

X post image

18 Mar 2022

⏰ In case you missed it

Is dara-(C)VRd pre- & post-ASCT the way forward for treatment of high-risk MM & PCL? Are digital comparators the future of trial design? Check out our summary of @MyMKaise presenting data from OPTIMUM/MUKnine at #ASH21
👉 https://t.co/l91Ih0ClYT 👈 #mmsm

X post image

24 Feb 2022

After 2 years of maintenance therapy with daratumumab + lenalidomide, what results have been seen in the Griffin trial for patients with NDMM? Find a summary of the data reported at #ASH21 here
👉 https://t.co/cro1SoqSxA 👈
#myeloma #mmsm

X post image

23 Feb 2022

⏰ Catch up on this ⏰

📹 #ASH21 | The MM Hub was pleased to speak to @End_myeloma, @UABNews. We asked, Is there still a role in multiple #myeloma for auto-SCT after induction with a quadruplet combination? 👀 #mmsm
https://t.co/5u0WK2GQWd

X post image

21 Feb 2022

⌛ In case you missed it ⌛

📹 #ASH21 | The MM Hub was pleased to speak to @TMSchmidtMD, University of Wisconsin-Madison, Madison, US. We asked, Where does carfilzomib fit in the current multiple #myeloma treatment landscape? 🩺 #mmsm
https://t.co/S1PClquniD

X post image

18 Feb 2022

🔎 Updated results of the phase I MagnetisMM-1 trial of elranatamab in patients with relapsed/refractory multiple #myeloma were presented at #ASH21. To find out the new ORR and safety data, check out our summary here
👉 https://t.co/GDICAhfi1i 👈
#mmsm

X post image

16 Feb 2022

RT @gvhd_hub: Following an informative session on healthcare disparities in bone marrow transplants at #ASH21 we examine the issues and pot…

X post image

15 Feb 2022

71% of pts reached an MRD-free, treatment-free state, with a low risk of MRD reappearance after 12 months in selected subgroups.
#ASH21 #mmsm #myeloma

X post image

14 Feb 2022

⏰ In case you missed it ⏰

📹 #ASH21 | The MM Hub was pleased to speak to @BrunoPaiva_UNAV, @unav. We asked, could CTCs and tumor DNA be more sensitive than a BM aspirate to assess treatment response in multiple #myeloma? 👀 #mmsm
https://t.co/sv96hkJ2jt

X post image

10 Feb 2022

What were the key findings of the @iStopMM trial presented at #ASH21 this year? 📚 Read this article for a summary 👉 https://t.co/0u7iUP9OgC 👈
#mmsm #myeloma @SigrunThorstei1 @sykristinsson

X post image

4 Feb 2022

📹 #ASH21 | The Multiple #Myeloma Hub was pleased to speak to Sonja Zweegman, @amsterdamumc. We asked, What are the results of treatment with ixazomib + daratumumab in intermediate-fit patients❓ #mmsm
https://t.co/S9S6jFYWo2

X post image

31 Jan 2022

🔎 Results of the GMMG-HD7 trial from #ASH21. How did the CD38 monoclonal antibody impact MRD when added to RVd❓
👉 https://t.co/VMf4QKWz9C 👈
#mmsm #myeloma

X post image

28 Jan 2022

📹 #ASH21| The MM Hub was pleased to speak to @mvmateos, University Hospital of Salamanca, Salamanca, ES. We asked, In which scenarios a PI added to lenalidomide-dexamethasone (Rd) maintenance could benefit patients with MM after auto-HSCT? #myeloma #mmsm
https://t.co/2tSiDiLfPH

X post image

24 Jan 2022

📹 #ASH21 | The Multiple Myeloma Hub was pleased to speak to @mvmateos, University Hospital of Salamanca, Salamanca, ES. We asked, What can we achieve with novel mass spectrometry techniques ❓ #myeloma #mmsm
https://t.co/89tDPXDt7X

X post image

19 Jan 2022

🎧Listen to this #ASH21 podcast🎧
The MM Hub was pleased to speak to Jacob Laubach, @DanaFarber & Peter Voorhees, @LevineCancer. We asked, Daratumumab as maintenance therapy for transplant-eligible NDMM: What have we learnt from GRIFFIN & CASSIOPEIA trials?https://t.co/EOuwMqIXzD

X post image

14 Jan 2022

Is dara-(C)VRd pre- & post-ASCT the way forward for treatment of high-risk MM & PCL❓ Are digital comparators the future of trial design? 📚 Check out our summary of @MyMKaiser presenting compelling data from OPTIMUM/MUKnine at #ASH21
👉 https://t.co/l91Ih0ClYT 👈
#myeloma #mmsm

X post image

27 Dec 2021

🌟#ASH21 is over but you can still find the latest updates in multiple #myeloma from our live congress coverage in this Twitter moment! 👇 #mmsm
📽️Stay tuned for summary articles, expert interviews and podcasts from #ASH21!
https://t.co/u2cRuJs31E

X post image

17 Dec 2021

Catch up on the @MM_Hub coverage from #ASH21 here 👉 https://t.co/jYWPR0IvXo to watch and read the latest in #MultipleMyeloma !

Thanks for tuning in for now – look out on our social media channels for congress content coming soon in 2022!

X post image

14 Dec 2021

#ASH21 | Black patients are under-represented in CT that supported CAR-T therapies approvals for various #hemeonc indications, but especially in #myeloma. Lack of access to #CARTcell may results in further widening of existent disparities #HealthDisparities
By @HadidiSamer #mmsm

X post image

14 Dec 2021

RT @IreneGhobrial: Confirmed by 2 other cohorts. You can improve on 20-2-20 with genomic classifier. #mmsm #ash21

X post image

14 Dec 2021

RT @Mohty_EBMT: Academia can also develop CAR-T cells. Congratulations to the Barcelona colleagues ⁦@ainitaoliver⁩ #ASH21 ⁦@Mohty_EBMT⁩ ⁦@C…

X post image

14 Dec 2021

We hope you enjoyed the ASH Annual Meeting as much as we did!

We’ve put together some #HotTopics discussed at #ASH21

Follow the link below to view the hot topics and related abstracts👇
https://t.co/tq8DxuHz0N

#Hematology #MultipleMyeloma #ASHAnnualMeeting #MedicalCongress

X post image

13 Dec 2021

RT @ALL_Hub_: #ASH21|Mycal Casey: Geographical distribution of trials may limit access. Underrepresentation is a complicated problem to res…

X post image

13 Dec 2021

RT @ALL_Hub_: #ASH21|Mycal Casey, Medical College of Georgia at Augusta University: Black/African-Americans are underrepresented in the cli…

X post image

13 Dec 2021

📍#ASH21 | FLC MALDI-TOF MS provided greater sensitivity for detection of residual monoclonal FLC and residual disease in patients in CR. Hannah Giles reports its association with reduced PFS and potential as prognostic indicator #mmsm @CRUKresearch

X post image

13 Dec 2021

📍#ASH21 | Tarek H Mouhieddine shares the outcomes of patients progressing to a bispecific antibody in @IcahnMountSinai. Sequential use of different T-cell engaging therapies seems feasible, although most patients received these therapies in dose-escalation trials #mmsm

X post image

13 Dec 2021

#ASH21 | Head to the MM Hub to review the data previously reported on Ven+Dd in patients with t(11;14) #mmsm https://t.co/FSkLvCikcP

X post image

13 Dec 2021

📍#ASH21 | @kaufman_MMdoc presents the updated data of combining venetoclax with daratumumab + dex in relapsed #myeloma. This new regimen will be soon evaluated in a randomized clinical trial. #mmsm

X post image

13 Dec 2021

📍#ASH21 | Our SC member, Shaji Kumar @myelomaMD and @kaufman_MMdoc kicking-off the last #myeloma session! #mmsm

X post image

13 Dec 2021

CONGRESS | #ASH21 | @DrSGandalf @helsinkiuni talks about NK cells in MM highlighting that there are molecular changes that may determine susceptibility to NK cell treatment. #mmsm #myeloma

X post image

13 Dec 2021

CONGRESS | #ASH21 | Mirco Friedrich @DKFZ presents TCR sequencing data on TCE responsiveness in RRMM patients. bsAbs induce expansion then contraction of the TCRs, cytotoxic CD8+ T cells may drive response, & non-responders show limited clonal replacement. #mmsm #myeloma

X post image

13 Dec 2021

CONGRESS | #ASH21 | @ovanoekelen @IcahnMountSinai presents data from a study of pre- and post-treatment with iberdomide in RRMM. There were major changes in the tumour microenvironment, with activation of adaptive immune cells in heavily pretreated patients. #mmsm #myeloma

X post image

13 Dec 2021

CONGRESS | #ASH21 | Lukas John @DKFZ presents WGS and scRNA-seq data from MM cells from NDMM patients, highlighting differences in mutational profiles between focal lesions (FL) & random BM aspirates highlighting that relapse seems to arise from FL subclones. #mmsm #myeloma

X post image

13 Dec 2021

CONGRESS | #ASH21 | @ChristieVerkle1 @amsterdamumc discusses part A of the DARA-ATRA study. DARA resistance was associated with an increased proportion of NK cells with an exhausted phenotype, suggesting reinvigoration of NK cells may restore cytotoxic capacities. #mmsm #myeloma

X post image

13 Dec 2021

CONGRESS | #ASH21 | Sarah K Johnson @uamscancer describes immune alterations associated with progression identified via CyTOF in pre and malignant stages of MM. Early changes in the immune microenvironment can result in immune suppression, evasion, and then MM. #mmsm #myeloma

X post image

13 Dec 2021

RT @Mohty_EBMT: Myeloma news LIVE from #ASH21 by @theIACH today Monday 13th of Dec. at 8PM CET. https://t.co/WTsKNoePkg

X post image

13 Dec 2021

📹 #ASH21 | The MM Hub was pleased to speak to @End_myeloma, @UABNews. We asked, Is there still a role in multiple #myeloma for auto-SCT after induction with a quadruplet combination? 👀 #mmsm
https://t.co/5u0WK2GQWd

X post image

12 Dec 2021

CONGRESS #ASH21| Tomas Jelinek @vsbtuostrava discusses circulating tumour cells as prognostic markers. There was significantly higher proportion of patients with ISS III stage, elevated LDH level & high risk cytogenetics associated with increasing number of cPCs #myeloma #mmsm

X post image

12 Dec 2021

📍#ASH21 | During the Q&A about #TcellRx in #myeloma there was a Q regarding the reporting of CARTs results in the ITT population, which includes production failures #mmsm

🔎We reviewed this topic recently on the Hub, take a look and share your thoughts! https://t.co/CDsDbstWRA

X post image

12 Dec 2021

#ASH21 In case you missed it 📰 https://t.co/XAXZ5bexEV

X post image

12 Dec 2021

#ASH21 | @TomBmt133 shares the updated results of cilta-cel in R/R #myeloma. At a med f-up of almost 2 years, ORR was 98%, with higher sCR rates (82.5%) vs 1-y.
2-y PFS and OS were 60.5% and 74%, respectively. Further improvement in patients with sustained MRD-neg #TcellRx #mmsm

X post image

12 Dec 2021

#CARTcell #mmsm #myeloma #ASH21 https://t.co/m4qTE3lisL

X post image

12 Dec 2021

RT @lymphomahub: #ASH21| 📢 Black pts are underrepresented in CAR-T clinical trials + efforts need to be made to enroll more Black pts in th…

X post image

12 Dec 2021

RT @lymphomahub: #ASH21|calculated prevalence-corrected estimates for enrollment of Black pts in CAR-T trials showed that Black pts constit…

X post image

12 Dec 2021

CONGRESS #ASH21 | Noemi Puig @usal presents analysis of accessible sampling techniques with data from PETHEMA trial of VRD+HDT. The presence or absence of disease by IFE did not ID pts with different PFS, but both mass spec & NGF split 2 cohorts with sig diff PFS #myeloma #mmsm

X post image

12 Dec 2021

#ASH21 | Neurotoxic events with b21217 were reported in 15% of patients.#mmsm #TcellRx

Learn more about neurotoxicity reported with anti-BCMA agents in our recent review on the Hub: https://t.co/dpHqFlEWDZ

X post image

12 Dec 2021

📍#ASH21 | b21217 already achieved a longer duration of response and median PFS than ide-cel (same construct), suggesting that the enriched expansion of memory-like T cell is improving outcomes in R/R #myeloma #mmsm @NoopurRajeMD @MGHCancerCenter

X post image

12 Dec 2021

CONGRESS #ASH21 | @VisramAlissa @MayoClinic speaks about using the Mayo 2018 & IMWG 2020 scores to stratify SMM pts post-diagnosis. Pts evolving to a risk cat during FU had an increased risk of progression vs pts with a stable/decreased risk cat using both scores #myeloma #mmsm

X post image

12 Dec 2021

CONGRESS #ASH21| Þórir Einarsson Long @uni_iceland discusses defining the ref interval of decreased kidney function & assess prev of LC-MGUS among CKD pts & found current ref intervals for serum FLC & FLC ratio are inaccurate for pts with decreased kidney function. #myeloma #mmsm

X post image

12 Dec 2021

CONGRESS #ASH21| @BurgosLeire @ClinicaNavarra describes an algorithm for automated recognition of #myeloma, MGUS & AL pts with flow. Pts with MGUS-like phenotype treated with modern intensive regimens showed good outcomes with fixed treatment duration regardless of CR #mmsm

X post image

12 Dec 2021

📍#ASH21 | CT103A kicks-off the #TcellRx session in #myeloma.
Stay tuned! #mmsm
https://t.co/zs7pWPVpAh

X post image

12 Dec 2021

📍#ASH21 | Data presented by @TMSchmidtMD today supports the addition of +1q and del1p in the high-risk #myeloma definition. KRd might achieve better survival outcomes for patients harboring gain1q and del1p at diagnosis. #mmsm

X post image

12 Dec 2021

RT @lymphomahub: 🔥#ASH21📍| @DrFredLocke @MoffittNews ZUMA7 KEY POINTS: 359 pts with R/R DLBCL ≤12 months after 1L anti-CD20 + anthracycline…

X post image

12 Dec 2021

#ASH21 Another great finding of this trial: Patients with MRD neg at 2 years who discontinued treatment did better than those with MRD who continued with Rd for 3 additional years. The 10% with MRD- who relapsed were mostly ISS II-III (only charact associated with relapse) #mmsm

X post image

12 Dec 2021

📍#ASH21 | Laura Rosiñol @hospitalclinic surprised the room with the GEM2014MAIN results: IRd maintenance shows no benefit vs Rd in patients who responded to VRd induction + auto-SCT. Dose reductions and discontinuations could partially explain the results #mmsm #bmtsm

X post image

12 Dec 2021

#ASH21 | Most patients were able to finish the planned cycles of Dara-CVRd with bortezomib dose-modifications. #mmsm

🤓 You can learn more on the OPTIMUM/MUKnine trial on the Hub: https://t.co/GeAzKYQUV1

X post image

12 Dec 2021

📍#ASH21 | @MyMKaiser presents the OPTIMUM/MUKnine trial with Dara-CVRd. This sc + oral regimen in ultra-high-risk #myeloma is superior to KCRD and CRD (Myeloma XI) when digitally compared #mmsm

X post image

12 Dec 2021

RT @MM_Hub: #ASH21 | New therapeutic options for patients relapsing after BCMA-direct agents are a growing unmet need in #mmsm; if all were…

X post image

12 Dec 2021

CONGRESS | #ASH21 | Anthony Battram @hospitalclinic, shows comparable in vitro and in vivo functions of CAR-T cells from apheresis products before and after G-CSF administration, despite G-CSF decreasing the CD8+ stem cell memory pool #mmsm

X post image

12 Dec 2021

RT @MM_Hub: 📹 #ASH21 | The MM Hub was pleased to speak to @TMSchmidtMD, University of Wisconsin-Madison, Madison, US. We asked, why should…

X post image

12 Dec 2021

CONGRESS #ASH21 | Hartmut Goldschmidt @UniHeidelberg describes the results of the phase III GMMG-HD6 trial which added elotuzumab to RVd. Adding elotuzumab to RVd induction/consolidation therapy & lenalidomide maintenance did not result in improved PFS or OS #mmsm #MYELOMA

X post image

12 Dec 2021

CONGRESS #ASH21 | @NicoGagelmann @UKEHamburg presents outcomes of NDMM pts with EMD post ASCT. Early outcome after maintenance start appeared to be significantly worse for organ involvement, with 1-yr PFS of 58% vs 81% for paraskeletal involvement & 82% for no EMD. #mmsm #MYELOMA

X post image

12 Dec 2021

Congress| #ASH21| Alfredo De La Torre, @pmcancercentre, discusses the impact of tandem transplant and clone size in patient with multiple #myeloma with a del17p mutation. He concludes tandem transplant improves outcomes and deepens response in this patient population. #MMsm

X post image

12 Dec 2021

Congress| #ASH21| Yujun Dai, Sun Yat-sen University Cancer Center, presents data identifying neuregulin-2 as a novel drug sensitivity biomarker for venetoclax in patients with non-t(11;14) multiple #myeloma. #MMsm

X post image

12 Dec 2021

CONGRESS #ASH21| Susan Bal @ONealCancerUAB talks about the benefit of AHCT following quadruplet therapy in #myeloma. 26% pts were MRD<10-6 post induction, increasing to 51% post-AHCT. Of the 60% who remained MRD+ve post-induction, 83% had a reduction in MRD burden with AHCT #mmsm

X post image

12 Dec 2021

📍#ASH21 | The IFM 2018-01 trial explores MRD rates with Dara-IRd in standard-risk ND #myeloma. @PerrotAurore highlights that MRD neg rates were ⬇️ vs Dara-VTd or Dara-KRd, but due to its improved safety profile, this regimen could be used in patients with comorbidities #mmsm

X post image

12 Dec 2021

Congress| #ASH21| @DrSarahGooding, @UniofOxford, describes how the loss of COP9 signalosome gene-containing 2q region is associated with lenalidomide and pomalidomide resistance in patients with #myeloma. #MMsm

X post image

12 Dec 2021

CONGRESS #ASH21| Blessie Elizabeth Nelson @MDAndersonNews talks about pts with refractory AL #amyloidosis who have ASCT. With a median FU of 3.11 yrs, the 3-yr PFS & OS for all were 67% & 78%, respectively. 3 mo post transplant, 74% of the refractory group achieved an OHR. #mmsm

X post image

12 Dec 2021

RT @AuclairDan: More on this MASTER presentation at #ASH21 #mmsm

X post image

12 Dec 2021

RT @AuclairDan: MASTERful, from ⁦@End_myeloma⁩ at #ASH21 .Anyone still has doubts that MRD has value in #myeloma trials and that MRD-based…

X post image

12 Dec 2021

#ASH21 | Hartmut Goldschmidt @uniklinik_hd presents the GMMG-HD7 trial, powered to evaluate MRD neg after induction with isatuximab + VRd vs VRd in ND #myeloma. Response rate was similar regardless cytogenetic risk, but MRD data still needs to be analyzed #mmsm

X post image

12 Dec 2021

Congress| #ASH21| @paularstrpo, @IcahnMountSinai, presents a novel gene expression signature comprised of 3 genes, WNT10A, DUSP1, and ETV7, which can predict response to selinexor-based therapy in patients with multiple #myleoma. #MMsm

X post image

12 Dec 2021

CONGRESS #ASH21 | @End_myeloma @uabmedicine discusses the results of the Master trial of Dara-KRd in newly diagnosed multiple #myeloma post-autologous transplant. Overall, 80% of pts have achieved MRD negativity and 66 % MRD < 10-6. 2-year PFS was 87% and 2-year OS was 94% #mmsm

X post image

12 Dec 2021

It’s here! #ASH21 has begun and is in full swing! Watch out for updates over the following days for the latest content from #ASH21 brought to you by the @MM_Hub! #MultipleMyeloma #mmsm

X post image

12 Dec 2021

📍#ASH21 | #SHEmatology Fantastic education session led by the MM Hub co-chair, @mvmateos, on the current challenges in multiple #myeloma with @Ashley_Rosko1 and @NoopurRajeMD #mmsm

X post image

12 Dec 2021

📹 #ASH21 | The MM Hub was pleased to speak to @TMSchmidtMD, University of Wisconsin-Madison, Madison, US. We asked, Where does carfilzomib fit in the current multiple #myeloma treatment landscape? 🩺 #mmsm
https://t.co/S1PClquniD

X post image

12 Dec 2021

Ready for day 2? #ASH21 @sci_ed_support #MMsm

X post image

12 Dec 2021

#ASH21 | New therapeutic options for patients relapsing after BCMA-direct agents are a growing unmet need in #mmsm; if all were available, how would you treat patients relapsing after BCMA?

X post image

12 Dec 2021

📍#ASH21 | @SagarLonialMD presents iberdomide + dex updated data, including a cohort in anti-BCMA-exposed patients.
Of note, with Iber, there is a significant reduction of non-hematological AEs classically related to other immunomodulatory drugs #mmsm @EmoryMedicine

X post image

12 Dec 2021

📍#ASH21 | Preclinical studies showed that adding dara increases talquetamab-mediated lysis. This trial included 65% of patients refractory to anti-CD38 and 55% with previous exposure to anti-BCMA and achieved high ORR. CRS in 55% of patients, G1-2. #mmsm https://t.co/v8ElPaKXI3

X post image

12 Dec 2021

📍#ASH21 | Suzanne Trudel @pmcancercentre shows the latest results with cevostamab (anti-FcRH5), including patients previously treated with CAR-Ts and anti-BCMA agents. RP2D not identified yet, but double step-up dose improved CRS profile #mmsm

X post image

12 Dec 2021

RT @AuclairDan: Finally, in the last @iStopMM presentation today at #ASH21 , in the RCT portion it was shown that active monitoring identif…

X post image

12 Dec 2021

RT @HadidiSamer: #ASH21 #mmsm iStopMM study SMM abstract🧵1/3
➡️Great efforts, population epidemiological screening study (~75,000)
➡️Preval…

X post image

12 Dec 2021

RT @HadidiSamer: #ASH21 #mmsm Promise study
👏 #ASHKudos for working on getting more African Americans screened/enrolled
➡️MGUS more common…

X post image

12 Dec 2021

#ASH21 | The MonumenTAL-1 trial enrolled patients with previous exposure to BCMA-directed agents: numbers are small and combine different immunotherapeutic agents and different doses of talquetamab, but responses seem consistent with the overall cohort #mmsm

X post image

12 Dec 2021

📍#ASH21 | With talquetamab (anti-GPRC5D × CD3 bsAb), skin-related AEs are experienced by 75% of patients, particularly exfoliation and rashes. @DoctorAKrishnan @CityofHopeOC underlines the learning curve that we are seeing with CRS management with these novel therapies #mmsm

X post image

12 Dec 2021

📍#ASH21 | Cyrille Touzeau @CHUNantes presents the I-Dara trial for frail patients with R/R #myeloma. Early toxicity is highlighted still as an important factor of this combination that might improve with dara SC, because it won’t need that much steroids #mmsm

X post image

12 Dec 2021

#ASH21 | During the live Q&A, @thanosdimop asked:
If you were to design a ph III pivotal trial for this combination, what would be your control arm? #mmsm Share your thoughts!👇@the_kaz_man #HOVON

X post image

12 Dec 2021

📍#ASH21 | Kaz Groen @CancerCenterAms shares the results of Ixa + dara + low-dex in intermediate-fit patients. HR-QOL outcomes improved, although 46% did not proceed to maintenance and 11% discontinued ixazomib. Read our summary of this combo in frail pts: https://t.co/shVrczLdcl

X post image

12 Dec 2021

📍#ASH21 | Higher conversion to MRD negative is seen with Dara + len maintenance after 2 years #mmsm https://t.co/0CGovNAE9i

X post image

12 Dec 2021

RT @Mohty_EBMT: Definitely, the GRIFFIN schema should be the standard of care in transplant-eligible myeloma patients. #ASH21 ⁦@Mohty_EBMT⁩…

X post image

12 Dec 2021

RT @VincentRK: A great slide from @TomBmt133 on bispecific antibodies in myeloma. #ASH21

Oncologists: Save this slide. Note the high sing…

X post image

11 Dec 2021

#ASH21📍| Daratumumab maintenance in the CASSIOPEIA trial deepened responses with longer f-up.Pending Q: Dara upfront (induction & consolidation) and/or after (maint)? Does early vs late MRD neg impact outcomes? Alone or with len? Presented by H Avet-Louiseau #mmsm

X post image

11 Dec 2021

Welcome to #ASHtlanta #ASH21
Fascinating morning hearing the latest updates in novel targets and ph II and III trials in #myeloma. Stay tuned! #mmsm

X post image

11 Dec 2021

#ASH21 This trial reported an important rate of early deaths in the Ven-Bd arm despite receiving infection prophylaxis. A possible explanation is patients non-t(11-14) for who venetoclax was only adding toxicities, and borte dose needed to be reduced. Share your thoughts! #mmsm

X post image

11 Dec 2021

📍#ASH21 | Updated analysis of the BELLINI trial presented by @myelomaMD @mayoclinic Significant longer PFS is seen in patients with t(11;14) and/or BLC2 high with the venetoclax triplet. Further development of venetoclax in this patient subgroup is planned for 2022 #mmsm

X post image

11 Dec 2021

RT @BrunoPaiva_UNAV: CASSIOPEIA MRD data at #ASH21 presented by Herve Avet-Loiseau. New and important observations:

Dara maintenance (vs o…

X post image

11 Dec 2021

📹 #ASH21 | The MM Hub was pleased to speak to @TMSchmidtMD, University of Wisconsin-Madison, Madison, US. We asked, why should chromosome 1 abnormalities be assessed in all patients with multiple #myeloma? 👀 #mmsm
https://t.co/TJjbARkS8x

X post image

10 Dec 2021

📢 1 day left for #ASH21 ⌛
🔥 Check out our what's hot in multiple #myeloma list for the top abstracts to look out for! 👀 #mmsm
https://t.co/tq8DxuHz0N

X post image

10 Dec 2021

Are you wondering what coverage the @MM_Hub will provide from #ASH21? Our team is working on bringing you virtual coverage, summary articles, and the latest expert opinions from leaders in #MultipleMyeloma !

We cannot wait for #ASH21 to begin tomorrow! #mmsm

X post image

9 Dec 2021

📚 Read more about cilta-cel in our hub #mmsm
👉 https://t.co/61n8Z0t4Jn 👈

👀 Stay tuned for more updates at #ASH21

X post image

9 Dec 2021

📹 #ASH21 | The MM Hub was pleased to speak to @BrunoPaiva_UNAV, @unav. We asked, could CTCs and tumor DNA be more sensitive than a BM aspirate to assess treatment response in multiple #myeloma? 👀 #mmsm
https://t.co/sv96hkrqUT

X post image

8 Dec 2021

🔎 We will cover the initial results with a similar combination at #ASH21

📚 The same strategy has been tested before with BCMA-directed CAR T cells and antibody drug conjugates. Read more in our hub
👉https://t.co/s4Qu9HaVbY 👈

X post image

7 Dec 2021

📢 With #ASH21 right around the corner, check out our what's hot in multiple #myeloma list for the top abstracts to look out for! #mmsm
https://t.co/tq8DxuHz0N

X post image

4 Dec 2021

The @MM_Hub will be covering #ASH21 and will bring you the latest updates in #MultipleMyeloma from the congress! Watch out on our social media channels for updates on what we have lined up for you from the 11th of December!

X post image

15 Nov 2021

RT @NicoGagelmann: Really happy to prepare #ASH21 talk on maintenance in #myeloma with/without extramedullary disease. Among all important…

X post image

15 Nov 2021

RT @ASH_hematology: Our featured hashtags can help you with #ASH21-specific posts, but we have also compiled a list of hashtags to help you…

X post image

11 Nov 2021

RT @ASH_hematology: Make the most of your #ASH21 experience whether you're joining virtually or heading to Atlanta! 💻✈️ This year's feature…

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

ASH 2021 American Society of Hematology

Your opinion matters

Regarding bispecific antibodies for multiple myeloma, which of the following do you consider the biggest hurdle for patients and caregivers?

Newsletter

Subscribe to get the best content delivered to your inbox